Lipocine
Open
$2.34
Prev. Close
$2.35
High
$2.34
Low
$2.31
Market Snapshot
$16.79M
-1.5
0.01
$11.2M
14
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 14 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 14 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Recently from Cashu
Lipocine Showcases LPCN 1154 for Innovative Postpartum Depression Treatment at 2026 Conference
Lipocine Inc. (Ticker: LPCN) is making strides in the biopharmaceutical industry with its innovative drug candidates aimed at treating postpartum depression and other major health issues. The company…
Lipocine Faces Setback as LPCN 1154 Fails Phase 3 Trial for Postpartum Depression
Lipocine Inc. (NASDAQ:LPCN) experiences a challenging moment as its LPCN 1154 medication aimed at postpartum depression (PPD) fails a pivotal Phase 3 clinical trial. This setback significantly impacts…
Mixed Results for Lipocine’s LPCN 1154 in Postpartum Depression Trial, Yet Promising Subset Data
Lipocine’s LPCN 1154: Mixed Results in Postpartum Depression Trial, But Promising Data Emerges Lipocine Inc. presents a nuanced picture following the topline results of its Phase 3 trial involving LPC…
Lipocine Advances Innovative Therapies for Postpartum Depression and Major Depressive Disorder
Lipocine Advances Postpartum and Major Depressive Disorder Treatments with Innovative Therapies Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company specializing in advanced oral delivery systems…